|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2004-9-23
|
|
pubmed:abstractText |
The efficacy and toxicity of combined therapy with irinotecan (CPT-11) plus mitomycin-C (MMC) were evaluated in patients with advanced or recurrent squamous cell carcinoma (SCC) of the uterine cervix.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0090-8258
|
|
pubmed:author |
pubmed-author:FujiiTuneoT,
pubmed-author:FushikiHiroshiH,
pubmed-author:HasegawaKazuoK,
pubmed-author:IzumiRikuichiR,
pubmed-author:Japan Gynecologic Oncology Group,
pubmed-author:NishidaMasatoM,
pubmed-author:NishimuraRyuichiroR,
pubmed-author:TakizawaKenK,
pubmed-author:TanakaTetsujiT,
pubmed-author:UmesakiNaohikoN,
pubmed-author:YamamotoKaichiroK
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
95
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
127-32
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:15385121-Adult,
pubmed-meshheading:15385121-Aged,
pubmed-meshheading:15385121-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15385121-Camptothecin,
pubmed-meshheading:15385121-Carcinoma, Squamous Cell,
pubmed-meshheading:15385121-Female,
pubmed-meshheading:15385121-Humans,
pubmed-meshheading:15385121-Middle Aged,
pubmed-meshheading:15385121-Mitomycin,
pubmed-meshheading:15385121-Neoplasm Recurrence, Local,
pubmed-meshheading:15385121-Prospective Studies,
pubmed-meshheading:15385121-Uterine Cervical Neoplasms
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Phase II study of irinotecan combined with mitomycin-C for advanced or recurrent squamous cell carcinoma of the uterine cervix: the JGOG study.
|
|
pubmed:affiliation |
Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama 641-0012, Japan. umesaki@wakayama-med.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II
|
